{"id":8094,"date":"2021-11-06T07:31:04","date_gmt":"2021-11-06T07:31:04","guid":{"rendered":"https:\/\/ncrfrontlinenews.com\/?p=8094"},"modified":"2021-11-06T07:31:04","modified_gmt":"2021-11-06T07:31:04","slug":"bharat-biotechs-partner-seeks-covaxin-approval-in-us-for-children-below-18-years","status":"publish","type":"post","link":"https:\/\/ncrfrontlinenews.com\/?p=8094","title":{"rendered":"Bharat Biotech\u2019s partner seeks Covaxin approval in US for children below 18 years"},"content":{"rendered":"<p>New Delhi: Bharat Biotech\u2019s US partner Ocugen has announced that it had asked the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18.<\/p>\n<p>\u201cWe are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners- Ocugen,\u201d tweeted Dr Raches Ella, Bharat Biotech\u2019s clinical lead for Covid-19 vaccines.<\/p>\n<p>The World Health Organisation (WHO) on Wednesday granted approval for Emergency Use Listing (EUL) for Bharat Biotech\u2019s COVID-19 vaccine, Covaxin.<\/p>\n<p>The approval was done on the recommendation of the Technical Advisory Group (TAG) for Emergency Use Listing (TAG-EUL), an independent advisory panel that provides recommendations to WHO on whether a COVID-19 vaccine can be listed for emergency use under the EUL procedure.<\/p>\n<p>Bharat Biotech\u2019s Covaxin and AstraZeneca and Serum Institute\u2019s Covishield are the two widely used vaccines in India.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Delhi: Bharat Biotech\u2019s US partner Ocugen has announced that it had asked the US Food and Drug Administration (FDA) for Emergency Use Authorisation (EUA) of Covaxin for children below 18. \u201cWe are pleased to announce our EUA filing to the US-Food and Drug Administration (FDA) through our partners- Ocugen,\u201d tweeted Dr Raches Ella, Bharat [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":8095,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"post-8094","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8094"}],"version-history":[{"count":1,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8094\/revisions"}],"predecessor-version":[{"id":8096,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/posts\/8094\/revisions\/8096"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=\/wp\/v2\/media\/8095"}],"wp:attachment":[{"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ncrfrontlinenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}